MSL Hematology West/North West Germany
Reports into Medical Lead Hematology
Field based role
Opportunity
This is an exciting opportunity for an experienced Medical Professional looking for a new challenge in an environment where your impact will be instantly visible. It is a chance to become an integral member of a small, highly motivated team tasked with delivering results and given the autonomy to define how they are achieved.
Individuals inspired by the possibility to raise awareness, educate and shape the medical landscape and prepare for the launch of new first in class therapies will thrive in this role.
Responsibilities
- Works closely with the Medical department to continue to establish a medical foot-print for Menarini-Stemline in the region
- Establishes, develops and manages collaborative relationships with key medical experts and opinion leaders of Germany related to any current and future disease areas relevant for Menarini-Stemline
- Drives disease awareness in providing external medical disease education and setting up local scientific programs, such as symposia, regional advisory boards, or scientific meetings in accordance with the respective Menarini-Stemline disease plans
- Coordinates and pro-actively contributes to all pre-launch and life cycle activities for Selinexor in the region
- Provides medical support and medical information on unsolicited HCP requests related to any Menarini-Stemline in-label and pipe-line products in accordance with the relevant Menarini-Stemline processes and local regulations
- Is an active member of scientific and educational interactions with therapeutic specialists on diagnostic and clinically relevant aspects of any therapeutic areas in which Menarini-Stemline is active.
- Locally facilitates any patient access programs (EAP) to address high unmet medical needs if applicable
- Collects competitive intelligence and market insights within the region and treatment paradigms of any therapeutic areas relevant for Menarini-Stemline
- Pro-actively supports internal medical knowledge development and provides internal training for sales and other functions on any relevant disease and product related aspects, in alignment with Medical Affairs Europe
- Manages/supports local aspects of investigator-initiated trials or other research projects in alignment with Clinical Development and Medical Affairs
- On request through clinical development and operations supports delivery of patient enrolment in Menarini-Stemline clinical trials
- Ensures that all activities required by pharmacovigilance and risk management are planned, set-up and pursued in accordance to respective local laws in the various markets
- Ensures legal excellence and compliance in all medical activities as per Menarini-Stemline SOPs and local regulations
Skills/Knowledge
- Requires at least 3 years’ experience in the pharmaceutical industry in a similar role.
- Doctorate degree (MD, PhD, PharmD)
- Previous experience in Hematology ideally in Multiple Myeloma with solid contacts to top KOLs in Germany
- Previous experience of product launches is desired.
- A strong bio-science education background.
- Ability to understand and effectively communicate scientific and medical information to both internal and a variety of external customers.
- Proven ability to articulate brand medical messages in line with medical strategy in a compelling way to KOLs
- Track record in creating strong advocacy about the brand with targeted Opinion Leaders and other stakeholders with a strong understanding of data and brand medical strategy
- Mobile, willing to travel extensively in the region and to conferences.
- Strong communication skills, open style & pro-active
- Fluent English and German is essential
Menarini Stemline is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines and is launched in Germany.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and launched it in February to the US market with the EMA review process is ongoing.
Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.
Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.
In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.
